Recently, the influenza virus vector COVID-19 vaccine for intranasal spray developed by Xiamen University was selected as one of the TOP 10 Medicinal Biotechnology in China for 2022, announced on February 18th. This is not the first time that the research results from the National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University have been selected for the list. Since 2017, the center has had a total of five achievements selected as the TOP 10 Medicinal Biotechnology in China, including the first domestically-produced bivalent HPV vaccine (approved for market in 2019 and WHO PQ certified in 2021), the first domestically-produced 9-valent HPV vaccine (approved for clinical trials in 2017), and the world's first HIV urine self-test kit (approved for market in 2019), among others.
